Both the entities said that on April 22, 2010 at joint advisory committee meeting, FDA questioned the effectiveness of niacin included in the current Acurox formulation but cited no concerns with the snorting and intravenous abuse limiting features of the product. The companies expect to submit an NDA for Acurox tablets (without niacin) in early 2011.
King Pharmaceuticals and Acura are also planing to develop and submit NDA’s for two additional immediate release opioid analgesic products utilising Acura’s proprietary Aversion Technology; Vycavert (hydrocodone bitartrate/acetaminophen) tablets and Acuracet (oxycodone HCl/acetaminophen) tablets.
Like Acurox, these additional product candidates are patent protected compositions comprising a mixture of active and inactive ingredients intended to relieve pain and introduce limits and impediments to nasal and intravenous abuse.